Gene therapy 'incubator' to be built by 2029 in Lake Success Biogenesis Park, officials say
The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...
FierceBiotech13h
Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition
Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...
stocknews2h
3 Pharma Stocks to Watch as Gene Therapy Gains Momentum
The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...
BioSpace9h
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
Pharmaceutical Technology9h
Ocuphire and Opus Genetics merge to develop IRD gene therapy
Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...
Long Island Press2h
$430M BioGenesis Park To Put Long Island At Forefront Of Cell Therapy
Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...
FiercePharma8h
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
Long Island Business News23h
$430M cell and gene therapy hub planned for Long Island
Visiting Nassau County on Tuesday, Gov. Kathy Hochul announced plans for the New York BioGenesis Park, a $430 million, ...
Researchers flip genes on and off with AI-designed DNA switches
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...
Seeking Alpha3h
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
The significance of this is that it brings about the ability to obtain FDA approval for this AAV gene therapy without the need to run a phase 3 study. Even better, it has another positive worth ...
MyChesCo on MSN26m
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy
(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...